This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Actor Dolph Lundgren faced a life-threatening kidney cancer battle, initially diagnosed in ...

Roche’s Alecensa has become the first drug in the ALK inhibitor class to significantly improve disease-free survival across all disease stages in a phase 3 trial involving patients with ALK-positive ...

Alectinib is recommended, within its marketing authorisation, as an option for the adjuvant treatment of stage 1B (tumours 4 cm or larger) to 3A ALK-positive non-small-cell lung cancer (NSCLC) after ...

The Appraisal Committee has prepared a Final Draft Guidance (FDG) on Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer and submitted it to the Institute. The FDG has been ...

Alectinib should not be used in patients who are allergic to the drug, patients with the history of liver or lung disease, exposure to excessive sunlight, during pregnancy or breast feeding. Alectinib ...

Genprex (GNPX) has entered into a Sponsored Research Agreement – SRA – with the University of Michigan Rogel Cancer Center to study TUSC2, the tumor suppressor gene used in Genprex’s lead drug ...

Alectinib approved by US FDA for auxiliary treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who underwent tumor resection. Alectinib, a molecule ...

The US Food and Drug Administration (FDA) has approved alectinib (Alecensa, Genentech) in the adjuvant setting following tumor resection in patients with anaplastic lymphoma kinase (ALK)–positive ...

Results showed treatment with alectinib reduced the risk of disease recurrence or death by 76%. The Food and Drug Administration (FDA) has approved Alecensa (alectinib) for adjuvant treatment in ...

The FDA extended indications for alectinib (Alecensa) to include adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first such approval for an ALK inhibitor. The approval ...

Adjuvant alectinib improves disease-free survival compared with platinum-based chemotherapy among patients with resected ALK-positive non-small cell lung cancer (NSCLC), according to a study published ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...